Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias with Pembrolizumab (CR-GTP)
KCT0005469Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in trophoblastic tumour, sponsored by Merck & Co. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
trophoblastic tumour
Beyond the preview
Go deeper on KCT0005469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005469.